State Street
EVOK

State Street’s Evoke Pharma EVOK Stock Holding History

State Street’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-888
Closed -$5.64K – 4307
2024
Q2 		$5.64K Buy
+888
New +$5.35K ﹤0.01% 4346
2022
Q2 		– Sell
-574
Closed -$41K – 4949
2022
Q1 		$41K Buy
574
+68
+13% +$5.42K ﹤0.01% 4829
2021
Q4 		$41K Hold
506
– – ﹤0.01% 4727
2021
Q3 		$95K Buy
+506
New +$85.3K ﹤0.01% 4558

Other funds holding EVOK

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

State Street's EVOK Position: Q3 2024 in Review

State Street sold out of Evoke Pharma (EVOK) in Q3 2024, closing a stake of 888 shares — an estimated $5.64K sold.

State Street first reported a position in EVOK in Q3 2021 and held it in 4 quarters. The position peaked at $95K in Q3 2021. 12 funds tracked by Wall St. Rank hold EVOK as of Q3 2024.

  • State Street reported no remaining Evoke Pharma position as of Q3 2024 after selling out during the quarter.
  • State Street sold 888 Evoke Pharma shares in Q3 2024, an estimated $5.64K.
  • State Street first reported a position in Evoke Pharma in Q3 2021 and held it in 4 quarters.
  • State Street's Evoke Pharma position peaked at $95K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2024.

Based on State Street's 13F filing for Q3 2024, filed 14 Nov 2024.